Role of the Cdc25A phosphatase in human breast cancer

Journal of Clinical Investigation

Volumn 106, Issue 6, 2000, Pages 753-761

  Cangi, M Giulia ^a   Cukor, Barry ^a   Soung, Peggy ^a   Signoretti, Sabina ^a,b   Moreira Jr , Gilberto ^a   Ranashinge, Moksha ^a   Cady, Blake ^c   Pagano, Michele ^d   Loda, Massimo ^a,b,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PHOSPHATASE; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; ENZYME ASSAY; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL;

EID: 0033796031     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9174     Document Type: Article

References (26)

1. Lees, H. 1995. Cyclin dependent kinase regulation. Curr. Opin. Cell Biol. 7:773-780.
2. Sherr, C.J., and Roberts, J.M. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
3. DelSal, G., Loda, M., and Pagano, M. 1996. Cell cycle and cancer: critical events at the G1 restriction point. Crit. Rev Oncog. 7:127-142.
4. Pardee, A.M. 1989. G1 events and regulation of cell proliferation. Science. 246:603-614.
5. Draetta, G., and Eckstein, J. 1997. Cdc25 protein phosphatases in cell proliferation. Biochim. Biophys. Acta. 1332:M53-M63.
6. Sadhu, K., Reed, S.I., Richardson, H., and Russell, P. 1990. Human homolog of fission yeast cdc25 mitoric inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA. 87:5139-5143.
7. Galaktionov, K., and Beach, D. 1991. Specific activation of cdc 25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mirotic cyclins. Cell. 67:1181-1194.
8. Gabrielli, B.C., Lee, M.S., Walker, D.H., Piwnica-Worms, H., and Maller, J.L. 1992. Cdc25 regulates the phosphorylation and activity of the Xenopus cdk2 protein kinase complex. J. Biol. Chem. 267:18040-18046.
9. Sebastian, B., Kakizuka, A., and Hunter, T. 1993. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl. Acad. Sci. USA. 90:3521-3524.
10. Hoffmann, I., Draetta, G., and Karsenti, K. 1994. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13:4302-4310.
11. Lammer, C., et al. 1998. The cdc25B phosphacase is essential for the G2/M phase transition in human cells. J. Cell Sci. 111:2445-2453.
12. Jinno, S., et al., 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-1556.
13. Blomberg, I., and Hoffmann, I. 1999. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E-and cyclin A-dependent kinases. Mol. Cell. Biol. 19:6183-6194.
14. Mailand, N., et al. 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science. 288:1425-1429.
15. Molinari, M., Mercurio, C., Dominguez, J. Goubin, F., and Draetta, F.G. 2000. Human cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO J. In press.
16. Galaktionov, K., et al. 1995 CDC25 phosphatasesas potential human oncogenes. Science. 269:1575-1577.
17. Ma, Z.Q., Chua, S.S., DeMayo, F.J., and Tsai, S.Y. 1999. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene. 18:4564-4576.
18. Tan, P., et al. 1997. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1259-1263.
19. Magi-Galluzzi, C., et al. 1997. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76:37-51.
20. Pagano, M., et al. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:682-685.
21. Saha, P., Eichbaum, Q., Silberman, E.D., Mayer, B.J., and Dutta, A. 1997. p21CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. Mol. Cell. Biol. 17:4338-4345.
22. Gu, Y., Rosenblatt, J., and Morgan, D.O. 1992. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr18. EMBO J. 11:3995-4005.
23. Cady, B., et al. 1996. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch. Surg. 131:301-308.
24. Rosen, P.P., Groshen, S., Kinne, D.W., and Norton, L. 1993. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J. Clin. Oncol. 11:2090-2100.
25. Wenger, C.R., and Clark, G.M. 1998. S-phase fraction and breast cancer: a decade of experience. Breast Cancer Res. Treat. 51:255-265.
26. Dettmar, P., et al. 1997. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br. J. Cancer. 75:1525-1533.